Evotec-Almirall Team Advances Small Molecule Program to Preclinical Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 10 hours ago
0mins
Source: Yahoo Finance
- Rapid Development Progress: The collaboration between Evotec and Almirall has successfully nominated a small molecule preclinical development candidate within just two years, significantly outperforming standard industry timelines and showcasing Evotec's efficiency in drug discovery.
- Integrated Technology Advantage: The project leverages Evotec's AI/ML-driven R&D platforms, encompassing medicinal chemistry, DMPK, and in vitro biology, ensuring a seamless data-driven workflow that accelerates the candidate identification process.
- Market Demand Alignment: This initiative focuses on developing novel therapies for immune-mediated inflammatory skin diseases, addressing the urgent need for innovative treatment options in the market, which holds significant commercial potential.
- Strategic Partnership Value: The collaboration includes potential success-based milestone payments of up to €230 million, reflecting the deep expertise and shared goals of Evotec and Almirall in medical dermatology, indicating promising future success possibilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EVO
Wall Street analysts forecast EVO stock price to rise
3 Analyst Rating
2 Buy
0 Hold
1 Sell
Moderate Buy
Current: 3.090
Low
5.00
Averages
6.00
High
7.00
Current: 3.090
Low
5.00
Averages
6.00
High
7.00
About EVO
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Evotec-Almirall Team Advances Small Molecule Program to Preclinical Development
- Rapid Development Progress: The collaboration between Evotec and Almirall has successfully nominated a small molecule preclinical development candidate within just two years, significantly outperforming standard industry timelines and showcasing Evotec's efficiency in drug discovery.
- Integrated Technology Advantage: The project leverages Evotec's AI/ML-driven R&D platforms, encompassing medicinal chemistry, DMPK, and in vitro biology, ensuring a seamless data-driven workflow that accelerates the candidate identification process.
- Market Demand Alignment: This initiative focuses on developing novel therapies for immune-mediated inflammatory skin diseases, addressing the urgent need for innovative treatment options in the market, which holds significant commercial potential.
- Strategic Partnership Value: The collaboration includes potential success-based milestone payments of up to €230 million, reflecting the deep expertise and shared goals of Evotec and Almirall in medical dermatology, indicating promising future success possibilities.
See More
Evotec to Announce Q1 2026 Financial Results on May 6
- Earnings Announcement Schedule: Evotec SE will hold a webcast and conference call on May 6, 2026, to announce its Q1 2026 financial results and provide a business update, which is expected to attract significant attention from investors and analysts.
- Meeting Time and Format: The conference is scheduled for 2:00 PM CEST (12:00 PM GMT, 8:00 AM EDT), and participants must pre-register to receive dial-in details, ensuring smooth participation in the call.
- Company Background: Evotec is a life science company focused on drug discovery and development, leveraging breakthrough science and AI-driven innovation to accelerate the journey from concept to cure, showcasing strong market competitiveness.
- R&D Assets and Partnership Models: The company boasts over 100 proprietary R&D assets across key therapeutic areas such as oncology, cardiovascular, and metabolic diseases, and has established flexible partnership models with all Top 20 pharma companies and over 800 biotech firms, highlighting its significant position in the industry.
See More
Evotec CFO Paul Hitchin Resigns, Claire Hinshelwood Appointed
- Executive Change: Evotec SE announced that CFO Paul Hitchin will resign on April 30, citing personal reasons unrelated to the company, indicating potential challenges in executive stability.
- New Financial Chief: Claire Hinshelwood will take over as CFO on May 1, bringing over 30 years of financial leadership experience, particularly from her recent role as CFO at BMI Group, which is expected to introduce new financial strategies for the company.
- Stock Price Reaction: On Nasdaq, Evotec's shares rose 1.55% in after-hours trading to $3.28, reflecting market optimism regarding the new CFO's appointment, despite closing at $3.23 during regular trading.
- Market Confidence: Although executive changes can introduce uncertainty, the market's response suggests that investors maintain a positive outlook on Evotec's future financial management and strategic direction, which may influence its long-term stock performance.
See More
Evotec Appoints New Chief Operating Officer
- Executive Appointment: Evotec announced the appointment of Dr. Ingrid Müller as Chief Operating Officer, effective May 1, 2026, bringing over 20 years of international leadership experience to oversee global operations and the execution of the Horizon initiative.
- Strategic Execution: In her previous role as Vice President at CureVac, Dr. Müller successfully drove portfolio strategy and execution, and in senior roles at Sanofi and Fresenius Kabi, she strengthened supply chain resilience and achieved annual savings.
- Operational Efficiency Enhancement: As COO, Dr. Müller will focus on improving quality, productivity, and delivery capabilities, with expectations that her extensive operational and strategic background will drive Evotec's growth transformation and enhance its competitiveness in the life sciences sector.
- Global Team Collaboration: Dr. Müller expressed her eagerness to collaborate with the global team to further enhance operational excellence and quality, supporting Evotec's sustainable growth and reflecting the company's commitment to scientific and technological platforms.
See More
Evotec (EVO) Q3 2025 Earnings Call Transcript
See More
Evotec SE Reports Significant Revenue and Cost Savings in 2025
- Revenue Growth: In Q4 2025, Evotec SE reported a revenue increase of EUR 32.1 million, or 14.5%, reaching EUR 253.3 million, indicating strong market performance despite a slight 1.1% decline in full-year revenue.
- Significant EBITDA Improvement: Adjusted EBITDA surged by EUR 29.5 million, or 103.6%, to EUR 58 million in Q4 2025, reflecting substantial operational efficiency improvements that enhance financial resilience.
- Cost Savings Achieved: Evotec delivered over EUR 60 million in annualized cost savings in 2025 and reduced capital expenditures by approximately 60%, providing more funding for future investments and growth opportunities.
- Strategic Partnership Agreements: The $650 million agreement with Sandoz and milestone payments from BMS signify crucial advancements in Evotec's global health programs, expected to drive future revenue growth.
See More
Evotec-Almirall Team Advances Small Molecule Program to Preclinical Development
- Rapid Development Progress: The collaboration between Evotec and Almirall has successfully nominated a small molecule preclinical development candidate within just two years, significantly outperforming standard industry timelines and showcasing Evotec's efficiency in drug discovery.
- Integrated Technology Advantage: The project leverages Evotec's AI/ML-driven R&D platforms, encompassing medicinal chemistry, DMPK, and in vitro biology, ensuring a seamless data-driven workflow that accelerates the candidate identification process.
- Market Demand Alignment: This initiative focuses on developing novel therapies for immune-mediated inflammatory skin diseases, addressing the urgent need for innovative treatment options in the market, which holds significant commercial potential.
- Strategic Partnership Value: The collaboration includes potential success-based milestone payments of up to €230 million, reflecting the deep expertise and shared goals of Evotec and Almirall in medical dermatology, indicating promising future success possibilities.
See More
Evotec to Announce Q1 2026 Financial Results on May 6
- Earnings Announcement Schedule: Evotec SE will hold a webcast and conference call on May 6, 2026, to announce its Q1 2026 financial results and provide a business update, which is expected to attract significant attention from investors and analysts.
- Meeting Time and Format: The conference is scheduled for 2:00 PM CEST (12:00 PM GMT, 8:00 AM EDT), and participants must pre-register to receive dial-in details, ensuring smooth participation in the call.
- Company Background: Evotec is a life science company focused on drug discovery and development, leveraging breakthrough science and AI-driven innovation to accelerate the journey from concept to cure, showcasing strong market competitiveness.
- R&D Assets and Partnership Models: The company boasts over 100 proprietary R&D assets across key therapeutic areas such as oncology, cardiovascular, and metabolic diseases, and has established flexible partnership models with all Top 20 pharma companies and over 800 biotech firms, highlighting its significant position in the industry.
See More
Evotec CFO Paul Hitchin Resigns, Claire Hinshelwood Appointed
- Executive Change: Evotec SE announced that CFO Paul Hitchin will resign on April 30, citing personal reasons unrelated to the company, indicating potential challenges in executive stability.
- New Financial Chief: Claire Hinshelwood will take over as CFO on May 1, bringing over 30 years of financial leadership experience, particularly from her recent role as CFO at BMI Group, which is expected to introduce new financial strategies for the company.
- Stock Price Reaction: On Nasdaq, Evotec's shares rose 1.55% in after-hours trading to $3.28, reflecting market optimism regarding the new CFO's appointment, despite closing at $3.23 during regular trading.
- Market Confidence: Although executive changes can introduce uncertainty, the market's response suggests that investors maintain a positive outlook on Evotec's future financial management and strategic direction, which may influence its long-term stock performance.
See More
Evotec Appoints New Chief Operating Officer
- Executive Appointment: Evotec announced the appointment of Dr. Ingrid Müller as Chief Operating Officer, effective May 1, 2026, bringing over 20 years of international leadership experience to oversee global operations and the execution of the Horizon initiative.
- Strategic Execution: In her previous role as Vice President at CureVac, Dr. Müller successfully drove portfolio strategy and execution, and in senior roles at Sanofi and Fresenius Kabi, she strengthened supply chain resilience and achieved annual savings.
- Operational Efficiency Enhancement: As COO, Dr. Müller will focus on improving quality, productivity, and delivery capabilities, with expectations that her extensive operational and strategic background will drive Evotec's growth transformation and enhance its competitiveness in the life sciences sector.
- Global Team Collaboration: Dr. Müller expressed her eagerness to collaborate with the global team to further enhance operational excellence and quality, supporting Evotec's sustainable growth and reflecting the company's commitment to scientific and technological platforms.
See More
Evotec (EVO) Q3 2025 Earnings Call Transcript
See More
Evotec SE Reports Significant Revenue and Cost Savings in 2025
- Revenue Growth: In Q4 2025, Evotec SE reported a revenue increase of EUR 32.1 million, or 14.5%, reaching EUR 253.3 million, indicating strong market performance despite a slight 1.1% decline in full-year revenue.
- Significant EBITDA Improvement: Adjusted EBITDA surged by EUR 29.5 million, or 103.6%, to EUR 58 million in Q4 2025, reflecting substantial operational efficiency improvements that enhance financial resilience.
- Cost Savings Achieved: Evotec delivered over EUR 60 million in annualized cost savings in 2025 and reduced capital expenditures by approximately 60%, providing more funding for future investments and growth opportunities.
- Strategic Partnership Agreements: The $650 million agreement with Sandoz and milestone payments from BMS signify crucial advancements in Evotec's global health programs, expected to drive future revenue growth.
See More
